BlueBird's rare blood disorder drug gets breakthrough therapy status

(Reuters) - The U.S. Food and Drug Administration has designated BlueBird Bio Inc's blood disorder drug a breakthrough therapy, speeding up the treatment's development process. The company's shares rose nearly 7 percent in premarket trading. Breakthrough therapy designation is based on initial trial data and granted to drugs with the potential to treat serious diseases better than existing therapies. BlueBird's drug, LentiGlobin, aims to treat beta-thalassemia — a disease that results in lower levels of hemoglobin in the blood.



via Health News Headlines - Yahoo News http://ift.tt/166bQQi